Jungsoo Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jungsoo Chang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Michael Girardi
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA
3 shared publications - Trilokraj Tejasvi
Department of Dermatology, University of Michigan, 1500 E Medical Center Dr, Ann Arbor, MI, 48105, United States, 1 734-936-4054
3 shared publications - Albert Yang
Department of Dermatology, University of Michigan, 1500 E Medical Center Dr, Ann Arbor, MI, 48105, United States, 1 734-936-4054
2 shared publications - Allison C. Billi
Department of Dermatology, University of Michigan, Ann Arbor, MI, USA
2 shared publications - Joseph S. Durgin
Department of Pathology University of Michigan Ann Arbor Michigan USA
2 shared publications - Kelly Z. Young
Department of Dermatology, University of Michigan, 1500 E Medical Center Dr, Ann Arbor, MI, 48105, United States, 1 734-936-4054
2 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Elsevier in JAAD Case Reports
- Vol. 78, 115-118
Livedo racemosa within a presentation of mycosis fungoides
- 9 October 2026
- Published by Elsevier in JAAD Case Reports
- Vol. 78, 115-118
Open AccessLivedo racemosa within a presentation of mycosis fungoides
- Open Access
- 16 May 2026
- Published by Elsevier in JAAD Case Reports
- Vol. 73, 115-117
Rapid growth of a long-standing dermal nodule in a young Black man: Clinical correlation in an ALK-rearranged epithelioid/spindle cell tumor
- 16 May 2026
- Published by Elsevier in JAAD Case Reports
- Vol. 73, 115-117
Open AccessRapid growth of a long-standing dermal nodule in a young Black man: Clinical correlation in an ALK-rearranged epithelioid/spindle cell tumor
- Open Access
- 12 January 2026
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 9, e76674
Leveraging AI Large Language Models for Writing Clinical Trial Proposals in Dermatology: Instrument Validation Study
Background: Large language models (LLMs) are becoming increasingly popular in clinical trial design but have been underused in research proposal development. Objective: This study compared the performance of commonly used open access LLMs versus human proposal composition and review. Methods: A total of 10 LLMs were prompted to write a research proposal. Six physicians and each of the LLMs assessed 11 blinded proposals for capabilities and limitations in accuracy and comprehensiveness. Results: ChatGPT-o1 and Llama 3.1 were rated the most and least accurate, respectively, by human scorers. LLM scorers rated ChatGPT-o1 and DeepSeek R1 as the most accurate. ChatGPT-o1 and Llama 3.1 were rated as the most and least comprehensive, respectively, by human and LLM scorers. LLMs performed poorly on scoring proposals and, on average, rated proposals 1.9 points higher than humans for both accuracy and comprehensiveness. Conclusions: Paid versions of ChatGPT remain the highest-quality and most versatile option of the available LLMs. These tools cannot replace expert input but serve as powerful assistants, streamlining the development process and enhancing productivity.
- 12 January 2026
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 9, e76674
Open AccessLeveraging AI Large Language Models for Writing Clinical Trial Proposals in Dermatology: Instrument Validation Study
Background: Large language models (LLMs) are becoming increasingly popular in clinical trial design but have been underused in research proposal development. Objective: This study compared the performance of commonly used open access LLMs versus human proposal composition and review. Methods: A total of 10 LLMs were prompted to write a research proposal. Six physicians and each of the LLMs assessed 11 blinded proposals for capabilities and limitations in accuracy and comprehensiveness. Results: ChatGPT-o1 and Llama 3.1 were rated the most and least accurate, respectively, by human scorers. LLM scorers rated ChatGPT-o1 and DeepSeek R1 as the most accurate. ChatGPT-o1 and Llama 3.1 were rated as the most and least comprehensive, respectively, by human and LLM scorers. LLMs performed poorly on scoring proposals and, on average, rated proposals 1.9 points higher than humans for both accuracy and comprehensiveness. Conclusions: Paid versions of ChatGPT remain the highest-quality and most versatile option of the available LLMs. These tools cannot replace expert input but serve as powerful assistants, streamlining the development process and enhancing productivity.
- Open Access
- 28 August 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Leveraging Artificial Intelligence Large Language Models for Writing Clinical Trial Proposals in Dermatology (Preprint)
BACKGROUND Large language models (LLMs) are becoming increasingly popular in clinical trial design but have been underutilized in research proposal development. OBJECTIVE This study compares the performance of commonly used open access LLMs versus human proposal composition and review. METHODS Ten LLMs were prompted to write a research proposal. Six physicians and each of the LLMs assessed 11 blinded proposals for capabilities and limitations in accuracy and comprehensiveness. RESULTS Chat GPT o1 was rated the most accurate and LLaMA 3.1 the least accurate by human scorers. LLM scorers rated Chat GPT o1 and Deepseek R1 the most accurate. Chat GPT o1 was the most comprehensive and LLaMA 3.1 the least comprehensive by human and LLM scorers. LLMs performed poorly on scoring proposals, and on average rated proposals 1.9 points higher than humans for both accuracy and comprehensiveness. CONCLUSIONS Paid versions of ChatGPT remain the highest quality and most versatile option of available LLMs. These tools cannot replace expert input but serve as powerful assistants, streamlining the development process and enhancing productivity. CLINICALTRIAL n/a
- 28 August 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessLeveraging Artificial Intelligence Large Language Models for Writing Clinical Trial Proposals in Dermatology (Preprint)
BACKGROUND Large language models (LLMs) are becoming increasingly popular in clinical trial design but have been underutilized in research proposal development. OBJECTIVE This study compares the performance of commonly used open access LLMs versus human proposal composition and review. METHODS Ten LLMs were prompted to write a research proposal. Six physicians and each of the LLMs assessed 11 blinded proposals for capabilities and limitations in accuracy and comprehensiveness. RESULTS Chat GPT o1 was rated the most accurate and LLaMA 3.1 the least accurate by human scorers. LLM scorers rated Chat GPT o1 and Deepseek R1 the most accurate. Chat GPT o1 was the most comprehensive and LLaMA 3.1 the least comprehensive by human and LLM scorers. LLMs performed poorly on scoring proposals, and on average rated proposals 1.9 points higher than humans for both accuracy and comprehensiveness. CONCLUSIONS Paid versions of ChatGPT remain the highest quality and most versatile option of available LLMs. These tools cannot replace expert input but serve as powerful assistants, streamlining the development process and enhancing productivity. CLINICALTRIAL n/a
- 8 August 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (3) , 593-604
Enhanced Intratumoral Delivery of Immunomodulator Monophosphoryl Lipid A through Hyperbranched Polyglycerol–Coated Biodegradable Nanoparticles
- 8 August 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (3) , 593-604
Enhanced Intratumoral Delivery of Immunomodulator Monophosphoryl Lipid A through Hyperbranched Polyglycerol–Coated Biodegradable Nanoparticles
- Open Access
- 15 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
Current treatments for T cell malignancies encounter issues of disease relapse and off-target toxicity. Using T cell receptor (TCR)Vβ2 as a model, here we demonstrate the rapid generation of an off-the-shelf allogeneic chimeric antigen receptor (CAR)-T platform targeting the clone-specific TCR Vβ chain for malignant T cell killing while limiting normal cell destruction. Healthy donor T cells undergo CRISPR-induced TRAC, B2M and CIITA knockout to eliminate T cell-dependent graft-versus-host and host-versus-graft reactivity. Second generation 4-1BB/CD3zeta CAR containing high affinity humanized anti-Vβ scFv is expressed efficiently on donor T cells via both lentivirus and adeno-associated virus transduction with limited detectable pre-existing immunoreactivity. Our optimized CAR-T cells demonstrate specific and persistent killing of Vβ2+ Jurkat cells and Vβ2+ patient derived malignant T cells, in vitro and in vivo, without affecting normal T cells. In parallel, we generate humanized anti-Vβ2 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) by Fc-engineering for NK cell ADCC therapy.
- 15 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Open AccessGeneration and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
Current treatments for T cell malignancies encounter issues of disease relapse and off-target toxicity. Using T cell receptor (TCR)Vβ2 as a model, here we demonstrate the rapid generation of an off-the-shelf allogeneic chimeric antigen receptor (CAR)-T platform targeting the clone-specific TCR Vβ chain for malignant T cell killing while limiting normal cell destruction. Healthy donor T cells undergo CRISPR-induced TRAC, B2M and CIITA knockout to eliminate T cell-dependent graft-versus-host and host-versus-graft reactivity. Second generation 4-1BB/CD3zeta CAR containing high affinity humanized anti-Vβ scFv is expressed efficiently on donor T cells via both lentivirus and adeno-associated virus transduction with limited detectable pre-existing immunoreactivity. Our optimized CAR-T cells demonstrate specific and persistent killing of Vβ2+ Jurkat cells and Vβ2+ patient derived malignant T cells, in vitro and in vivo, without affecting normal T cells. In parallel, we generate humanized anti-Vβ2 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) by Fc-engineering for NK cell ADCC therapy.
- Open Access
- 21 September 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (9) , e0290763
Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: A study of the national ambulatory medical care survey from 2002–2016
Background: Acne vulgaris affects a significant number of females into adulthood. Juvenile acne and adult acne have different presentations and potentially distinctive pathogeneses. However, patterns in treatments specifically related to the adult female population have previously not been studied. Methods: Retrospective database analysis of healthcare utilization and medications prescribed for acne using the National Ambulatory Medical Care Survey (NAMCS) data from 2002–2016 was performed. Results: After age 20, acne accounted for an almost 2.5-fold higher proportion of dermatology visits among females compared to males (10.1% vs. 4.1%, P < 0.001). Tetracycline-class antibiotics were the most prescribed therapy within all age groups of females between 2002–2016. However, there was also a substantial rise in prescriptions of spironolactone beginning in 2012. Conclusion: A significantly greater proportion of dermatology visits by adult females are for acne in comparison to adult males. Tetracycline-class antibiotics remain the most prescribed therapy in adult age groups despite a potentially different pathogenesis of adult acne. Therefore, there is a need for further studies comparing the effectiveness of therapies specifically for adult female acne.
- 21 September 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (9) , e0290763
Open AccessAcne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: A study of the national ambulatory medical care survey from 2002–2016
Background: Acne vulgaris affects a significant number of females into adulthood. Juvenile acne and adult acne have different presentations and potentially distinctive pathogeneses. However, patterns in treatments specifically related to the adult female population have previously not been studied. Methods: Retrospective database analysis of healthcare utilization and medications prescribed for acne using the National Ambulatory Medical Care Survey (NAMCS) data from 2002–2016 was performed. Results: After age 20, acne accounted for an almost 2.5-fold higher proportion of dermatology visits among females compared to males (10.1% vs. 4.1%, P < 0.001). Tetracycline-class antibiotics were the most prescribed therapy within all age groups of females between 2002–2016. However, there was also a substantial rise in prescriptions of spironolactone beginning in 2012. Conclusion: A significantly greater proportion of dermatology visits by adult females are for acne in comparison to adult males. Tetracycline-class antibiotics remain the most prescribed therapy in adult age groups despite a potentially different pathogenesis of adult acne. Therefore, there is a need for further studies comparing the effectiveness of therapies specifically for adult female acne.
- Open Access
- 15 March 2023
- Published by Elsevier in JID Innovations
- Vol. 3 (4) , 100197
Nanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment
- 15 March 2023
- Published by Elsevier in JID Innovations
- Vol. 3 (4) , 100197
Open AccessNanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment